Recently, we have shown that the KRAS-variant, and other novel inherited mutations like it, appear to predict altered immunity, and possibly autoimmunity.
We first found that individuals with the KRAS-variant are immunosuppressed, resulting in unique responses to cancer therapy1, and likely explaining their increased cancer risk. We also are investigating the impact of the KRAS-variant on the flip-side of immunosuppression, which is autoimmunity, which is also associated with an increased risk of cancer.
Our findings with the KRAS-variant led us to investigate a large panel of genetic biomarkers like the KRAS-variant, which also disrupt microRNA signaling. We have now found that these biomarkers also predict altered immunity, as presented at American Society of Clinical Oncology (ASCO 2017).
If you or your family has a history of Myasthenia Gravis you may be eligible to participate in this study. Take the eligibility survey.
MiraKind’s research efforts are currently focused on understanding the impact of these novel mutations, including the KRAS-variant, on altered immunity. Please consider joining one of our studies through taking our research survey. If you are otherwise eligible for KRAS-variant testing, and would like to order testing without joining a study, please follow this link.
TAKE THE ELIGIBILITY SURVEY
We encourage you to see if you are eligible to join a MiraKind study to help us discover meaningful ways to better treat patients with genetic mutations. If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study. If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.
- Weidhaas, J.B., J. Harris, D. Schaue, A. Chen, R. Chin, R. Axelrod, A.K. El-Naggar, A.K. Singh, T.J. Galloway, D. Raben, D. Wang, C. Matthiesen, V. Avizonis, R.R. Manon, O. Yumen, P.F. Nguyen-Tan, A. Trotti, H. Skinner, Q. Zhang, R.L. Ferris, D. Sidransky, and C.H. Chung, The KRAS-variant and Cetuximab Response in Head and Neck Squamous Cell Cancer, A Secondary Analysis of a Randomized Cinical Trial. JAMA Oncology, 2017. 3(4): p. 483-491